SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia-related cytogenetics). 4 of those patients had myelomonocytic phenotype (M4 per FAB classification). The ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia ... in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia ... in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations ...

The company announced that the trial's Cohort 3 results showed a median overall survival (mOS) of 8.9 months in patients with AML-myelodysplasia-related ... GPS in Acute Myeloid Leukemia without ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009, a ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events ...